Exact Sciences Stock News

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ: EXAS ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 2 0 0 Last 30D 0 2 2 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Exact Sciences has an average price target of $95.0 with a high … Full story available on Benzinga.com

Exact Sciences Corp''s (NASDAQ: EXAS ) Q4 revenues increased 2% Y/Y to $473.8 million and beat the average Wall Street estimate of $449 million. Excluding COVID-19 testing revenues, which dropped 52% to $47.1 million, Exact''s Q4 revenue increased 16%. Screening revenues rose 11% to $277.7 million in Q4, while precision oncology revenues were up 27% at $149 million. The firm attributed its screening revenue growth to … Full story available on Benzinga.com

Exact Sciences, known for its Cologuard cancer test, reported good revenue growth in its December quarter. The follow-up conference call was spent on initiatives to tap big markets and reverse the stock''s yearlong slide.

The Ark Funds ETFs have been hit hard in 2022 with growth stocks among the laggards as investors turned to value stocks. Many stockholders have begun to question high multiples attached to once fav

Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increased 2% Y/Y to $473.8 million and beat the average Wall Street estimate of $449 million. Excluding COVID-19 testing revenues, which dropped 52%

Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.

EXAS earnings call for the period ending December 31, 2021.

EXAS earnings call for the period ending December 31, 2021.

Exact Sciences (EXAS) delivered earnings and revenue surprises of -40.66% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $220.6 million in its fourth quarter. The Madison, Wisconsin-based company said it had a loss of $1.28 per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed

A 47% year-over-year narrowing in its net loss still wasn''t enough for Exact Sciences (EXAS) to beat bottom-line consensus for Q4 2021.